Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
58.84
+0.47 (0.81%)
Dec 5, 2024, 4:00 PM EST - Market closed

Company Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.

The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis.

In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer.

It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company
Bristol-Myers Squibb Company logo
Country United States
Founded 1887
Industry Drug Manufacturers - General
Sector Healthcare
Employees 34,100
CEO Christopher Boerner

Contact Details

Address:
Route 206 & Province Line Road
Princeton, New Jersey 08543
United States
Phone 609 252 4621
Website bms.com

Stock Details

Ticker Symbol BMY
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000014272
CUSIP Number 110122108
ISIN Number US1101221083
Employer ID 22-0790350
SIC Code 2834

Key Executives

Name Position
Dr. Christopher S. Boerner Ph.D. Chief Executive Officer and Chairman
David V. Elkins Executive Vice President and Chief Financial Officer
Sandra Leung Esq. Executive Vice President and General Counsel
Samit Hirawat M.D. Executive Vice President, Chief Medical Officer and Head of Development
Greg Meyers Executive Vice President and Chief Digital and Technology Officer
Timothy Power Vice President and Head of Investor Relations
Kimberly M. Jablonski Chief Compliance and Ethics Officer
Ahn Amanda Poole Executive Vice President and Chief Human Resources Officer
Dr. Joseph J. Eiden Jr. Head of Medical Affairs
Adam Lenkowsky Executive Vice President, Chief Commercialization Officer and Head of U.S. Oncology

Latest SEC Filings

Date Type Title
Nov 4, 2024 144 Filing
Oct 31, 2024 10-Q Quarterly Report
Oct 31, 2024 8-K Current Report
Jul 26, 2024 10-Q Quarterly Report
Jul 26, 2024 8-K Current Report
Jun 25, 2024 11-K Annual report of employee stock purchase, savings and similar plans
Jun 25, 2024 11-K Annual report of employee stock purchase, savings and similar plans
Jun 25, 2024 11-K Annual report of employee stock purchase, savings and similar plans
Jun 18, 2024 8-K Current Report
May 9, 2024 8-K Current Report